1. At a Glance
Cravatex Ltd is that uncle at the wedding who has seen everything since 1951, still shows up well-dressed, but occasionally forgets what exactly he does for a living. With a market capitalisation of ₹98.7 crore and a current price of ₹382, the company looks deceptively calm on the surface. The stock is down about 10% over the last three months, down 15.5% over one year, yet still quietly paying a dividend yield of 3.27% like a retired government employee who never misses pension day. The latest quarterly numbers (Sep 2025) show sales of ₹51.45 crore with a net profit of ₹5.22 crore, translating into a quarterly EPS of ₹20.20. Annualised, that’s ₹80.8 per share, which suddenly makes the headline P/E ratios look… awkwardly low. ROCE sits at 6.57%, ROE at 4.68%, and debt is officially zero. On paper, this looks like a balance sheet yogi—light, flexible, and debt-free. But then you look at operating margins swinging like a pendulum and sales shrinking over the long term, and you realise this is not a Zen retreat; it’s more like CrossFit with occasional injuries.
2. Introduction
Cravatex Ltd was incorporated in 1951, which means it is older than independent India’s obsession with stock market apps. Originally, it was into dry cleaning—yes, starching collars and ironing trousers—before wandering through garment exports, textile processing, printing, and finally landing in branded sports goods and fitness equipment. This is not a pivot; this is a full-on career-change montage.
Today, Cravatex positions itself as a retail, brand licensing, distribution, and sourcing company under the Batra Group umbrella. Its biggest claim to fame is the exclusive sub-licensing and distribution of the FILA brand across India, Pakistan, Sri Lanka, and Bangladesh. Add to that a fitness equipment distribution business via Taiwan-based Johnson Health, and suddenly the company is selling both treadmills and tracksuits, hoping you’ll sweat in style.
But here’s the twist: despite operating in aspirational lifestyle categories, Cravatex’s financials resemble a veteran trader who knows how to survive but hasn’t figured out how to sprint. Revenue has been shrinking over the years, margins are inconsistent, and profits are often rescued by other income like a superhero arriving in the last scene. So the question is simple—are we looking at a misunderstood value relic, or just a very polite stagnation machine?
3. Business Model – WTF Do They Even Do?
Imagine explaining Cravatex to a friend who skipped finance class but knows brands. You’d say: “They don’t really manufacture much. They distribute cool stuff made by others, slap global branding on it, and try to make money moving boxes.”
Cravatex operates primarily in two segments. The first is sports—trading footwear, apparel, and accessories, which contributes roughly 98% of FY23 revenue. This is where FILA dominates the narrative. The second segment is wellness—gym equipment and accessories—contributing the remaining 2%. Yes, that treadmill business is more of a side hustle than a core revenue engine.
Internationally, Cravatex has reach through its UK subsidiary, BB (UK) Ltd, which provides design, development, and sourcing services to FILA license holders in the UK, Ireland, Middle East, and North Africa. So while the Indian listed entity looks small, parts of the ecosystem are global in flavour.
Geographically, FY23 revenue split shows ~77% from international markets and ~23% from domestic sales. That’s impressive exposure, but also means foreign demand cycles and licensing dynamics matter a lot. Cravatex doesn’t control the brand; it rents credibility. And as every Indian tenant knows, rent can go up, terms can change,
